Data collected by the National Institutes of Health shows that people who have received a shot of Johnson & Johnson’s coronavirus vaccine would be more likely if they received the mRNA shot instead of another J&J, according to the person who viewed the data. they have a strong neutralizing antibody response.
yes but: J&J has asked the FDA to authorize a second shot of its own vaccine, which could make any attempt to authorize mix-and-match vaccines confusing for the public.
state of play: An FDA advisory panel this week is considering booster shots for J&J recipients and some recipients of Moderna Vaccine.
- On Friday, when the panel will focus on J&K, the NIH will present findings from its mix-and-match booster study, according to draft agenda of meeting.
- This data is expected to show a significantly stronger neutralizing antibody response to an mRNA booster than to a second dose of J-J – a form of immune protection.
- But J&J hasn’t asked the FDA to authorize mixing and matching of its vaccine with another, which could mess up the process. It is unclear how the mix-and-match authorization process will go.
But, but, but: NIH data has limitations. Neutralizing antibodies are only one form of immune protection, and it is not clear how long the reaction will last.
Bottom-line: The most interesting part of Friday’s meeting may be how the panel addresses the questions that are not J&J is being asked by – but of significant interest to the 15 million Americans who got their shot.